Neurosterix

Geneva, Switzerland

Neurosterix is a biopharmaceutical firm dedicated to creating allosteric modulators for the treatment of neurological illnesses.

$63.0M raised

Apr 2024

Series A

Top Investors

Perceptive AdvisorsXontogenyAcorn Bioventures

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Neurosterix raised?

Neurosterix has raised $63.0M in total funding. The most recent round was Series A. The last funding was announced in April 2024.

Who are Neurosterix's investors?

Neurosterix's investors include Perceptive Advisors, Xontogeny, Acorn Bioventures.

Where is Neurosterix headquartered?

Neurosterix is headquartered in Geneva, Switzerland.

What does Neurosterix do?

Neurosterix is a biopharmaceutical firm dedicated to creating allosteric modulators for the treatment of neurological illnesses.

What stage is Neurosterix at?

Neurosterix is at the Series A stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated April 3, 2024.

MLA

"Neurosterix — Funding & Investors." VCBacked, April 3, 2024, https://www.vcbacked.co/company/neurosterix. Accessed June 17, 2026.

APA

VCBacked. (2024). Neurosterix — Funding & Investors. Retrieved June 17, 2026, from https://www.vcbacked.co/company/neurosterix

Wikipedia (cite web)

{{cite web |title=Neurosterix — Funding & Investors |url=https://www.vcbacked.co/company/neurosterix |website=VCBacked |access-date=June 17, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated April 3, 2024.